GSK agrees to pay up to $1.7 billion for antibody-drug conjugate
GSK PLC (GSK) said Wednesday that it has agreed to pay $185 million up front and up to $1.525 billion in success-based milestone payments to license an antibody-drug conjugate from Chinese biopharma company Hansoh Pharma (HK:3692). The deal gives GSK exclusive rights to further develop and commercialize the ADC, HS-20093, which in early studies has shown promise for the treatment of lung cancer. ADCs, which are designed to target cancer cells while minimizing harm to healthy cells, have spawned a number of licensing agreements and other deals lately, including an October agreement between GSK and Hansoh for an ADC focused on ovarian and endometrial cancer. AbbVie (ABBV) said late last month that it would acquire ImmunoGen Inc. (IMGN), whose key asset is an ADC for ovarian cancer. GSK plans to launch phase 1 trials for HS-20093 outside China in 2024, the company said in a release. GSK's American depositary receipts gained 0.2% premarket on Wednesday and are up 3.9% in the year to date, while the S&P 500 has gained 24%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-20-23 0828ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying